Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation

[1]  A. Roddam.  Analysing Survival Data from Clinical Trials and Observational Studies , 2005 .

[2]  K. Dietz,et al.  Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Ganser,et al.  Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Pepe.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[5]  S. Mastana,et al.  Molecular genetic variation in the East Midlands, England: analysis of VNTR, STR and Alu insertion/deletion polymorphisms , 2003, Annals of human biology.

[6]  G. Ehninger,et al.  Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. , 2002 .

[7]  O. Ringdén,et al.  Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation , 2001, Leukemia.

[8]  T. Lion,et al.  Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation , 2001, Leukemia.

[9]  D. Head.  Problematic WHO Reclassification of Myelodysplastic Syndromes , 2000 .

[10]  C. Schmoor,et al.  Allogeneic bone marrow transplantation from unrelated donors using in vivo anti‐T‐cell globulin , 2000, British journal of haematology.

[11]  M. V. van Oers,et al.  Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Holler,et al.  Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation , 2000, Bone Marrow Transplantation.

[13]  O. Ringdén,et al.  Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia , 2000, Bone Marrow Transplantation.

[14]  R. Collins,et al.  Donor leukocyte infusions for multiple myeloma , 2000, Bone Marrow Transplantation.

[15]  T. Lion,et al.  Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection , 1999, Leukemia.

[16]  T. Klingebiel,et al.  Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children , 1999, Leukemia.

[17]  J. Goldman,et al.  Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. , 1999, Experimental hematology.

[18]  H. Kolb.  Donor Leukocyte Transfusions for Treatment of Leukemic Relapse after Bone Marrow Transplantation , 1998, Vox sanguinis.

[19]  H. Einsele,et al.  Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT , 1998, Bone Marrow Transplantation.

[20]  J. Hancock,et al.  Minimal residual disease analysis for the prediction of relapse in children with standard‐risk acute lymphoblastic leukaemia , 1998, British journal of haematology.

[21]  A. Elmaagacli,et al.  Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. , 1998, Bone marrow transplantation.

[22]  A. Elmaagacli,et al.  Detection of CBFβ/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation , 1998, Bone Marrow Transplantation.

[23]  J. Cornelissen,et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. , 1997, Blood.

[24]  M. Stetler-Stevenson,et al.  Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad news , 1997, Bone Marrow Transplantation.

[25]  K. Cleary,et al.  Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect , 1997, Bone Marrow Transplantation.

[26]  E Marubini,et al.  Analysing Survival Data from Clinical Trials and Observational Studies; E. Marubini & M. G. Valsecchi Published by John Wiley & Sons 414 pages ISBN 0-971-93987-0. , 1995, British journal of clinical pharmacology.

[27]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[28]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. , 1995, Blood.

[29]  S. Tura,et al.  The presence of lymphoid‐associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance , 1995, Stem cells.

[30]  J. Goldman,et al.  Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.

[31]  J. Wijnen,et al.  Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. , 1994, Blood.

[32]  Z. Estrov,et al.  Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. , 1994, Leukemia.

[33]  J. Wijnen,et al.  Mixed T-lymphoid chimerism after allogeneic bone marrow transplantation for hematologic malignancies of children is not correlated with relapse. , 1993, Blood.

[34]  J. Bourhis,et al.  Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. , 1992, Blood.

[35]  D. S. Rath,et al.  Tetranucleotide repeat polymorphism at the human beta-actin related pseudogene H-beta-Ac-psi-2 (ACTBP2). , 1992, Nucleic acids research.

[36]  L. Jin,et al.  Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. , 1992, Genomics.

[37]  B Budowle,et al.  Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. , 1991, American journal of human genetics.

[38]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[39]  D. Smeets,et al.  Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. , 1989, Blood.

[40]  P. Simmons,et al.  Host origin of marrow stromal cells following allogeneic bone marrow transplantation , 1987, Nature.